Rangeley Capital’s Lifecore Biomedical LFCR Stock Holding History

Rangeley Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-43,700	Closed	-$325K	–	88
2024 Q4	$325K	Buy	+43,700	New	+$279K	0.29%	52

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return

Rangeley Capital's LFCR Position: Q1 2025 in Review

Rangeley Capital sold out of Lifecore Biomedical (LFCR) in Q1 2025, closing a stake of 43,700 shares — an estimated $325K sold.

Rangeley Capital first reported a position in LFCR in Q4 2024 and held it in 1 quarter. The position peaked at $325K in Q4 2024. 87 funds tracked by Wall St. Rank hold LFCR as of Q1 2025.

Rangeley Capital reported no remaining Lifecore Biomedical position as of Q1 2025 after selling out during the quarter.
Rangeley Capital sold 43,700 Lifecore Biomedical shares in Q1 2025, an estimated $325K.
Rangeley Capital first reported a position in Lifecore Biomedical in Q4 2024 and held it in 1 quarter.
Rangeley Capital's Lifecore Biomedical position peaked at $325K in Q4 2024.
87 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2025.

Based on Rangeley Capital's 13F filing for Q1 2025, filed 14 May 2025.